Medical eligibility criteria for new contraceptive methods: Combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant

Contraception

Volumn 73, Issue 2, 2006, Pages 134-144

  Gaffield, Mary E ^a   Curtis, Kathryn M ^b   Mohllajee, Anshu P ^b   Peterson, Herbert B ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Combined hormonal patch; Combined hormonal vaginal ring; Etonogestrel implant; Evidence based guidelines

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL;

BONE DENSITY; CHILD DEVELOPMENT; COCHRANE LIBRARY; CONTRACEPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG IMPLANT; DRUG SAFETY; ENDOMETRIOSIS; HUMAN; INFORMATION RETRIEVAL; LACTATION; MEDICAL LITERATURE; MEDLINE; PUERPERIUM; REVIEW; TRANSDERMAL PATCH; VAGINA RING;

ADMINISTRATION, CUTANEOUS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; DRUG IMPLANTS; FEMALE; HUMANS;

EID: 30644458569     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2005.08.002     Document Type: Review

References (44)

1. D. Wulf Sharing responsibility: women, society and abortion worldwide 1999 The Alan Guttmacher Institute New York
2. M. Zieman The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra) Fertil Steril 77 2002 S1 S2
3. J. Trussell Contraceptive failure in the United States Contraception 70 2004 89 96
4. R.T. Burkman The transdermal contraceptive patch: a new approach to hormonal contraception Int J Fertil 47 2002 69 76
5. Anonymous First contraceptive patch offers once-a-week dosing. FDA approves Ortho Evra transdermal contraceptive Contracept Technol Update 23 2002 1 3
6. F.J.M.E. Roumen, M.E. Boon, D. van Velzen, T.O.M. Dieben, and H. Coelingh The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring Hum Reprod 11 1996 2443 2448
7. H.B. Croxatto Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant Eur J Contracept Reprod Health Care 5 Suppl 2 2000 21 28
8. H. Coelingh Bennink Presentation of clinical data on Implanon® Contraception 58 1998 75S 77S
9. H.B. Croxatto, J. Urbancsek, R. Massai, H. Coelingh Bennink, A. van Beek and the Implanon® Study Group A multicentre efficacy and safety study of the single contraceptive implant Implanon® Hum Reprod 14 1999 976 981
10. J. Huber Pharmacokinetics of Implanon®. An integrated analysis Contraception 58 1998 85S 90S
11. H.B. Croxatto Mechanisms that explain the contraceptive action of progestin implants for women Contraception 65 2002 21 27
12. L. Makarainen, A. van Beek, L. Tuomivaara, B. Asplund, and H. Coelingh Bennink Ovarian function during the use of a single contraceptive implant: Implanon® compared with Norplant® Fertil Steril 69 1998 714 721
13. World Health Organization Improving access to quality care in family planning: medical eligibility criteria for contraceptive use 3rd ed. 2003 WHO Geneva
14. A.P. Mohllajee, K.M. Curtis, R.G. Flannagan, W. Rinehart, M.E. Gaffield, and H.B. Peterson Keeping up with the evidence: a new system for WHO's evidence-based family planning guidance Am J Prev Med 28 2005 483 490
15. A. Oxman Grading quality of evidence and strength of recommendations BMJ 328 2004 1490 1494
16. M.L. Rubinstein, B.L. Halpern-Felsher, and C.E. Irwin An evaluation of the use of the transdermal contraceptive patch in adolescents J Adolesc Health 34 2004 395 401
17. S. Logsdon, J. Richards, and H.A. Omar Long-term evaluation of the use of the transdermal contraceptive patch in adolescents Sci World J 4 2004 512 516
18. M.-C. Audet, M. Moreau, and W.D. Koltun Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive: a randomized controlled trial JAMA 285 2001 2347 2354
19. G.H. Smallwood, M.L. Meador, and J.P. Lenihan Efficacy and safety of a transdermal contraceptive system Obstet Gynecol 98 2001 799 805
20. F.M. Helmerhorst, H.S. Cronje, and B. Hedon Comparison of efficacy, cycle control, compliance and safety in users of a contraceptive patch vs. an oral contraceptive XVI FIGO World Congress of Gynecology and Obstetrics [FC 2.30.06], Washington DC, USA, 3-8 September 2000
21. R. Dittrich, L. Paker, and J.B. Rosen Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study Am J Obstet Gynecol 186 2002 15 20
22. R.A. Pierson, D.F. Archer, and M. Moreau Ortho Evra™/Evra™ versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error Fertil Steril 80 2003 34 42
23. L.S. Abrams, D.M. Skee, J. Natarajan, F.A. Wong, and G.D. Anderson Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyl estradiol at four application sites Br J Clin Pharmacol 53 2002 141 146
24. L.S. Abrams, D.M. Skee, J. Natarajan, F.A. Wong, and K.C. Lasseter Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants Contraception 64 2001 287 294
25. L.S. Abrams, D.M. Skee, and J. Natarajan Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra™/Evra™) under conditions of heat, humidity, and exercise J Clin Pharmacol 41 2001 1301 1309
26. T.O.M. Dieben, R.J.M.E. Roumen, and D. Apter Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring Obstet Gynecol 100 2002 585 593
27. K. Oddsson, B. Leifels-Fischer, and N.R. de Melo Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial Contraception 71 2005 176 182
28. R.I. Bjarnadottir, M. Tuppurainen, and S.R. Killick Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ ethinyl estradiol Am J Obstet Gynecol 186 2002 389 395
29. G.C. Davies, L.X. Feng, and J.R. Newton The effects of a combined contraceptive vaginal ring releasing ethinylestradiol and 3-ketodesogestrel on vaginal flora Contraception 45 1992 511 518
30. M. Tuppurainen, R. Klimscheffskij, M. Venhola, and T.O.M. Dieben The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: a comparative study Contraception 69 2004 389 394
31. E.M. Magnusdottir, R.I. Bjarnadottir, and P.T. Onundarson The combined contraceptive vaginal ring (NuvaRing®) and hemostasis: a comparative study Contraception 69 2004 461 467
32. I. Duijkers, S. Killick, A. Bigrigg, and T.O.M. Dieben A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function Eur J Contracept Reprod Health Care 3 2004 131 140
33. C.J. Timmer, and T.M.T. Mulders Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring Clin Pharmacokinet 39 2000 233 242
34. R. Beerthuizen, A. van Beek, R. Massai, J. in't Hout, and H. Coelingh Bennink Bone mineral density during long term use of the progestogen contraceptive implant Implanon® compared to a non-hormonal method of contraception Hum Reprod 15 2000 118 122
35. D. Reinprayoon, S. Taneepanichskul, and S. Bunyavejchevin Effects of the etonogestrel-releasing contraceptive implant (Implanon®) on parameters of breastfeeding compared to those of an intrauterine device Contraception 62 2000 239 246
36. S.B. Yisa, A.A. Okenwa, and R.P. Husmeyer Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon®) J Fam Plann Reprod Health Care 31 2005 67 70
37. A. Biswas, O.A.C. Viegas, H.J.T. Coelingh Bennick, T. Korver, and S. Ratman Effect of Implanon® use on selected parameters of thyroid and adrenal function Contraception 62 2000 247 251
38. A. Biswas, O.A.C. Viegas, H.J.T. Coelingh Bennick, T. Korver, and S. Ratman Implanon® contraceptive implants: effects on carbohydrate metabolism Contraception 63 2001 137 141
39. S. Suherman, B. Affandi, and T. Korver The effects of Implanon® on lipid metabolism in comparison with Norplant® Contraception 60 1999 281 287
40. A. Biswas, S. Biswas, and O.A.C. Viegas Effect of etonogestrel subdermal contraceptive implant (Implanon®) on liver function tests - a randomized comparative study with Norplant® implants Contraception 70 2004 379 382
41. J.E. Edwards, and A. Moore Implanon. A review of clinical studies Br J Fam Plann 24 1999 3 16
42. A. Smith, and S. Reuter An assessment of the use of Implanon® in three community services J Fam Plann Reprod Health Care 28 2002 193 196
43. R. Wenzl, A. van Beek, P. Schabel, and J. Huber Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon® Contraception 58 1998 283 288
44. M. Zieman, J. Guillebaud, E. Weisberg, G.A. Shangold, A.C. Fisher, and G.W. Creasy Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled data Fertil Steril 77 Suppl 2 2002 S13 S18